| 2026-11-17 Filed 2026-11-19 | Schuth Alexander O. Officer: COFO and Secretary | M Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 Common Stock | Acquired (A) | 16,566 | 9.60 | 159,033.6 Derived: shares × price per share. Exact value 159033.60. | 295,561 | Direct (D) | No | F1 - F1 Includes 135,475 Unvested RSUs.
| Open filing 0001724311-26-000016 Read from the filing’s XML Dispute this row |
| 2026-11-17 Filed 2026-11-19 | Schuth Alexander O. Officer: COFO and Secretary | M Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 Derivative security: Stock Option (right to buy) — underlying Common Stock (16,566) — exercise price 9.60 | Disposed (D) | 16,566 | 0 | — | 40,075 | Direct (D) | No | F3 - F3 25% of the shares subject to the option vested on August 22, 2018 and an additional 1/48 of the shares vest monthly thereafter.
| Open filing 0001724311-26-000016 Read from the filing’s XML Dispute this row |
| 2026-09-04 Filed 2026-09-09 | Chin Peter Scott Officer: Chief Medical Officer | S Open market or private sale of non-derivative or derivative security Common Stock | Disposed (D) | 1,654 | 22.29 | 36,867.66 Derived: shares × price per share. Exact value 36867.66. | 204,538 | Direct (D) | No | F1, F2, F3, F4 - F1 Shares sold to satisfy the tax obligations by the Reporting Person in connection with the settlement of previously vested restricted stock units.
- F2 The sale price reported in column 4 of Table I represents the weighted average sale price of the shares ranging from $22.28 to $22.29 per share. Upon request by the Commission staff, the Issuer, or a
security holder of the Issuer, the Reporting Person will provide full information regarding the number of shares sold at each separate price.
- F3 Includes 142,845 Unvested RSU's
- F4 Includes 1,790 shares acquired under the ESPP Purchase on June 1, 2026.
| Open filing 0002124755-26-000007 Read from the filing’s XML Dispute this row |
| 2026-09-02 Filed 2026-09-04 | Thornberry Nancy Director | S Open market or private sale of non-derivative or derivative security Common Stock | Disposed (D) | 10,824 | 22.85 | 247,328.4 Derived: shares × price per share. Exact value 247328.40. | 20,301 | Direct (D) | Yes | F1, F2, F3 - F1 The sales reported by the Reporting Person were affected pursuant to a Rule 10b5-1 trading plan adopted June 3, 2026.
- F2 The sale price reported in column 4 of Table I represents the weighted average sale price of the shares ranging from $22.54 to $23.52 per share. Upon request by the Commission staff, the Issuer, or a security holder of the Issuer, the Reporting Person will provide full information regarding the number of shares sold at each separate price.
- F3 Includes 6,408 Unvested RSUs.
| Open filing 0001797826-26-000006 Read from the filing’s XML Dispute this row |
| 2026-09-02 Filed 2026-09-04 | Thornberry Nancy Director | S Open market or private sale of non-derivative or derivative security Common Stock | Disposed (D) | 615 | 23.74 | 14,600.1 Derived: shares × price per share. Exact value 14600.10. | 19,686 | Direct (D) | Yes | F1, F4, F3 - F1 The sales reported by the Reporting Person were affected pursuant to a Rule 10b5-1 trading plan adopted June 3, 2026.
- F4 The sale price reported in column 4 of Table I represents the weighted average sale price of the shares ranging from $23.59 to $23.85 per share. Upon request by the Commission staff, the Issuer, or a security holder of the Issuer, the Reporting Person will provide full information regarding the number of shares sold at each separate price.
- F3 Includes 6,408 Unvested RSUs.
| Open filing 0001797826-26-000006 Read from the filing’s XML Dispute this row |
| 2026-09-01 Filed 2026-09-03 | Schuth Alexander O. Officer: COFO and Secretary | S Open market or private sale of non-derivative or derivative security Common Stock | Disposed (D) | 2,768 | 23.44 | 64,881.92 Derived: shares × price per share. Exact value 64881.92. | 278,995 | Direct (D) | Yes | F1, F2 - F1 The sales reported by the Reporting Person were affected pursuant to a Rule 10b5-1 trading plan adopted March 27, 2026.
- F2 Includes 135,475 Unvested RSUs.
| Open filing 0001724311-26-000014 Read from the filing’s XML Dispute this row |
| 2026-08-12 Filed 2026-08-14 | Watts Ryan J. Director · Officer: President and CEO | G Bona fide gift Common Stock | Disposed (D) | 32,220 | 0 | — | 2,120,384 | Indirect (I) See footnote | No | F1, F2 - F1 Reflects an in-kind charitable contribution of 32,220 shares of DNLI to a donor advised fund.
- F2 The shares are held of record by the Watts Family 2015 Trust dated July 7, 2015, for which the Reporting Person serves as trustee.
| Open filing 0001724310-26-000007 Read from the filing’s XML Dispute this row |
| 2026-08-11 Filed 2026-08-13 | Schuth Alexander O. Officer: COFO and Secretary | S Open market or private sale of non-derivative or derivative security Common Stock | Disposed (D) | 2,857 | 25.07 | 71,624.99 Derived: shares × price per share. Exact value 71624.99. | 281,763 | Direct (D) | No | F1, F2, F3 - F1 Shares sold to satisfy the tax obligations by the Reporting Person in connection with the settlement of previously vested RSUs.
- F2 Includes 135,475 Unvested RSUs.
- F3 Includes 1,792 shares acquired under the ESPP Purchase on June 1, 2026.
| Open filing 0001724311-26-000013 Read from the filing’s XML Dispute this row |
| 2026-06-03 Filed 2026-06-05 | Krognes Steve E. Director | A Grant, award or other acquisition pursuant to Rule 16b-3(d) Common Stock | Acquired (A) | 6,408 | 0 | — | 38,202 | Direct (D) | No | F1, F2 - F1 Each share is represented by a Restricted Stock Unit (RSU) and a contingent right to receive one share of common stock of the Issuer. 100% of the RSUs shall vest upon the earlier of (i) the one year anniversary of the grant date or (ii) the day preceding the Issuer's next annual meeting of stockholders occurring after the grant date.
- F2 Includes 6,408 unvested RSUs.
| Open filing 0001666236-26-000015 Read from the filing’s XML Dispute this row |
| 2026-06-03 Filed 2026-06-05 | Krognes Steve E. Director | A Grant, award or other acquisition pursuant to Rule 16b-3(d) Derivative security: Stock Option (right to buy) — underlying Common Stock (19,226) — exercise price 19.66 | Acquired (A) | 19,226 | 0 | — | 19,226 | Direct (D) | No | F4 - F4 100% of the shares subject to the option shall vest upon the earlier of (i) the one year anniversary of the grant date or (ii) the day preceding the Issuer's next annual meeting of stockholders occurring after the grant date.
| Open filing 0001666236-26-000015 Read from the filing’s XML Dispute this row |
| 2026-06-03 Filed 2026-06-05 | Schenkein David P Director | A Grant, award or other acquisition pursuant to Rule 16b-3(d) Common Stock | Acquired (A) | 6,408 | 0 | — | 21,665 | Direct (D) | No | F1, F2 - F1 Each share is represented by a Restricted Stock Unit (RSU) and a contingent right to receive one share of common stock of the Issuer. 100% of the RSUs shall vest upon the earlier of (i) the one year anniversary of the grant date or (ii) the day preceding the Issuer's next annual meeting of stockholders occurring after the grant date.
- F2 Includes 6,408 unvested RSUs.
| Open filing 0001578200-26-000004 Read from the filing’s XML Dispute this row |
| 2026-06-03 Filed 2026-06-05 | Schenkein David P Director | A Grant, award or other acquisition pursuant to Rule 16b-3(d) Derivative security: Stock Option (right to buy) — underlying Common Stock (19,226) — exercise price 19.66 | Acquired (A) | 19,226 | 0 | — | 19,226 | Direct (D) | No | F5 - F5 100% of the shares subject to the option shall vest upon the earlier of (i) the one year anniversary of the grant date or (ii) the day preceding the Issuer's next annual meeting of stockholders occurring after the grant date.
| Open filing 0001578200-26-000004 Read from the filing’s XML Dispute this row |
| 2026-06-03 Filed 2026-06-05 | BAKER BROS. ADVISORS LP Director667, L.P. DirectorBaker Bros. Advisors (GP) LLC DirectorBaker Brothers Life Sciences LP DirectorBAKER FELIX DirectorBAKER JULIAN Director | A Grant, award or other acquisition pursuant to Rule 16b-3(d) Common Stock | Acquired (A) | 6,408 | 0 | — | 343,275 | Indirect (I) See Footnotes | No | F1, F2, F3, F4, F5, F6, F7, F8 - F1 Includes 6,408 restricted stock units (each, an RSU) payable solely in common stock (Common Stock) of Denali Therapeutics Inc. (the Issuer) granted by the Issuer to Julian C. Baker, a managing member of Baker Bros. Advisors (GP) LLC (the Adviser GP) on June 3, 2026, pursuant to the Issuer's 2017 Equity Incentive Plan and Outside Director Compensation Policy (collectively the Incentive Plan). The RSUs vest on the earlier of June 3, 2027 or the day prior to the Issuer's Annual Meeting occurring after June 3, 2026, subject to Julian C. Baker's continuous service on the board of directors of the Issuer (the Board) through such vesting date. Julian C. Baker serves on the Board as a representative of 667, L.P. (667) and Baker Brothers Life Sciences, L.P. (Life Sciences, and together with 667, the Funds) and their affiliates and control persons.
- F2 After giving effect to the transactions reported herein and as a result of their ownership interest in (i) Baker Biotech Capital, L.P. and (ii) 667, Julian C. Baker and Felix J. Baker each may be deemed to have an indirect pecuniary interest in Common Stock reported in column 5 of Table I and the Stock Options (as defined below) reported in column 9 of Table II held directly by or held for the benefit of 667, a limited partnership of which the sole general partner is Baker Biotech Capital, L.P., a limited partnership of which the sole general partner is Baker Biotech Capital (GP), LLC, due to their interest in 667 and Baker Biotech Capital, L.P.'s right to receive an allocation of a portion of the profits from 667.
- F3 Pursuant to the policies of the Adviser, Julian C. Baker does not have a right to any of the Issuer's securities issued as compensation for his service on the Board and the Funds are entitled to an indirect proportionate pecuniary interest in such securities. The Funds each own an indirect proportionate pecuniary interest in the non-qualified stock options exercisable solely into Common Stock (Stock Options) and RSUs. Solely as a result of their ownership interest in (i) the general partners of the Funds and (ii) the Funds, Felix J. Baker and Julian C. Baker may be deemed to have an indirect pecuniary interest in the Stock Options, RSUs and any Common Stock acquired upon the exercise of Stock Options or vesting of RSUs (i.e. no direct pecuniary interest) issued as compensation for such Board Service.
- F4 Baker Bros. Advisors LP (the Adviser) serves as the investment adviser to the Funds. In connection with the services provided by the Adviser, the Adviser receives an asset-based management fee that does not confer any pecuniary interest in the securities held directly by the Funds or for the benefit of the Funds. The Adviser GP is the Adviser's sole general partner. Julian C. Baker and Felix J. Baker are managing members of the Adviser GP. The Adviser has complete and unlimited discretion and authority with respect to the investment and voting power of the securities held directly by the Funds or for the benefit of the Funds. The general partners of the Funds relinquished to the Adviser all discretion and authority with respect to the investment and voting power of the securities held directly by the Funds or for the benefit of the Funds.
- F5 Julian C. Baker, Felix J. Baker, the Adviser GP and the Adviser disclaim beneficial ownership of the securities held directly by or held for the benefit of the Funds except to the extent of their pecuniary interest therein, and this report shall not be deemed an admission that any of Julian C. Baker, Felix J. Baker, the Adviser GP or the Adviser is a beneficial owner of such securities for purposes of Section 16 or any other purpose.
- F6 Pursuant to the policies of the Adviser, the Adviser has voting and dispositive power over the Stock Options, RSUs and any Common Stock received as a result of the exercise of Stock Options or vesting of RSUs.
- F7 The acquisitions of the RSUs and Stock Options reported on this form represent a single grant to Julian C. Baker of 6,408 RSUs on Table I and 19,226 Stock Options on Table II. These grants, totaling 6,408 RSUs and 19,226 Stock Options for Julian C. Baker, are reported for each of the Funds as each has an indirect pecuniary interest in such securities.
- F8 Includes beneficial ownership of 2,641 shares of Common Stock received previously from vested RSUs and 7,924 shares of Common Stock underlying unvested RSUs that were issued to Julian C. Baker in his capacity as a director of the Issuer, each of which the Funds are deemed to own a portion.
| Open filing 0001193125-26-259680 Read from the filing’s XML Dispute this row |
| 2026-06-03 Filed 2026-06-05 | BAKER BROS. ADVISORS LP Director667, L.P. DirectorBaker Bros. Advisors (GP) LLC DirectorBaker Brothers Life Sciences LP DirectorBAKER FELIX DirectorBAKER JULIAN Director | A Grant, award or other acquisition pursuant to Rule 16b-3(d) Common Stock | Acquired (A) | 6,408 | 0 | — | 3,422,366 | Indirect (I) See Footnotes | No | F1, F3, F4, F5, F6, F7, F8, F9 - F1 Includes 6,408 restricted stock units (each, an RSU) payable solely in common stock (Common Stock) of Denali Therapeutics Inc. (the Issuer) granted by the Issuer to Julian C. Baker, a managing member of Baker Bros. Advisors (GP) LLC (the Adviser GP) on June 3, 2026, pursuant to the Issuer's 2017 Equity Incentive Plan and Outside Director Compensation Policy (collectively the Incentive Plan). The RSUs vest on the earlier of June 3, 2027 or the day prior to the Issuer's Annual Meeting occurring after June 3, 2026, subject to Julian C. Baker's continuous service on the board of directors of the Issuer (the Board) through such vesting date. Julian C. Baker serves on the Board as a representative of 667, L.P. (667) and Baker Brothers Life Sciences, L.P. (Life Sciences, and together with 667, the Funds) and their affiliates and control persons.
- F3 Pursuant to the policies of the Adviser, Julian C. Baker does not have a right to any of the Issuer's securities issued as compensation for his service on the Board and the Funds are entitled to an indirect proportionate pecuniary interest in such securities. The Funds each own an indirect proportionate pecuniary interest in the non-qualified stock options exercisable solely into Common Stock (Stock Options) and RSUs. Solely as a result of their ownership interest in (i) the general partners of the Funds and (ii) the Funds, Felix J. Baker and Julian C. Baker may be deemed to have an indirect pecuniary interest in the Stock Options, RSUs and any Common Stock acquired upon the exercise of Stock Options or vesting of RSUs (i.e. no direct pecuniary interest) issued as compensation for such Board Service.
- F4 Baker Bros. Advisors LP (the Adviser) serves as the investment adviser to the Funds. In connection with the services provided by the Adviser, the Adviser receives an asset-based management fee that does not confer any pecuniary interest in the securities held directly by the Funds or for the benefit of the Funds. The Adviser GP is the Adviser's sole general partner. Julian C. Baker and Felix J. Baker are managing members of the Adviser GP. The Adviser has complete and unlimited discretion and authority with respect to the investment and voting power of the securities held directly by the Funds or for the benefit of the Funds. The general partners of the Funds relinquished to the Adviser all discretion and authority with respect to the investment and voting power of the securities held directly by the Funds or for the benefit of the Funds.
- F5 Julian C. Baker, Felix J. Baker, the Adviser GP and the Adviser disclaim beneficial ownership of the securities held directly by or held for the benefit of the Funds except to the extent of their pecuniary interest therein, and this report shall not be deemed an admission that any of Julian C. Baker, Felix J. Baker, the Adviser GP or the Adviser is a beneficial owner of such securities for purposes of Section 16 or any other purpose.
- F6 Pursuant to the policies of the Adviser, the Adviser has voting and dispositive power over the Stock Options, RSUs and any Common Stock received as a result of the exercise of Stock Options or vesting of RSUs.
- F7 The acquisitions of the RSUs and Stock Options reported on this form represent a single grant to Julian C. Baker of 6,408 RSUs on Table I and 19,226 Stock Options on Table II. These grants, totaling 6,408 RSUs and 19,226 Stock Options for Julian C. Baker, are reported for each of the Funds as each has an indirect pecuniary interest in such securities.
- F8 Includes beneficial ownership of 2,641 shares of Common Stock received previously from vested RSUs and 7,924 shares of Common Stock underlying unvested RSUs that were issued to Julian C. Baker in his capacity as a director of the Issuer, each of which the Funds are deemed to own a portion.
- F9 After giving effect to the transactions reported herein and as a result of their ownership interest in (i) Baker Brothers Life Sciences Capital, L.P. and (ii) Life Sciences, Julian C. Baker and Felix J. Baker each may be deemed to have an indirect pecuniary interest in Common Stock reported in column 5 of Table I and the Stock Options reported in column 9 of Table II held directly by or held for the benefit of Life Sciences, a limited partnership of which the sole general partner is Baker Brothers Life Sciences Capital, L.P., a limited partnership of which the sole general partner is Baker Brothers Life Sciences Capital (GP), LLC, due to their interest in Life Sciences and Baker Brothers Life Sciences Capital, L.P.'s right to receive an allocation of a portion of the profits from Life Sciences.
| Open filing 0001193125-26-259680 Read from the filing’s XML Dispute this row |
| 2026-06-03 Filed 2026-06-05 | BAKER BROS. ADVISORS LP Director667, L.P. DirectorBaker Bros. Advisors (GP) LLC DirectorBaker Brothers Life Sciences LP DirectorBAKER FELIX DirectorBAKER JULIAN Director | A Grant, award or other acquisition pursuant to Rule 16b-3(d) Derivative security: Non-Qualified Stock Option (right to buy) — underlying Common Stock (19,226) — exercise price 19.66 | Acquired (A) | 19,226 | 0 | — | 19,226 | Indirect (I) See Footnotes | No | F10, F2, F3, F4, F5, F6, F7 - F10 19,226 Stock Options exercisable solely into Common Stock were granted under the Incentive Plan to Julian C. Baker in his capacity as a director of the Issuer. The Stock Options have a strike price of $19.66 and expire on June 3, 2036. The Stock Options vest on the earlier of June 3, 2027 or the day prior to the Issuer's Annual Meeting occurring after June 3, 2026, subject to Julian C. Baker's continuous service on the Board through such vesting date.
- F2 After giving effect to the transactions reported herein and as a result of their ownership interest in (i) Baker Biotech Capital, L.P. and (ii) 667, Julian C. Baker and Felix J. Baker each may be deemed to have an indirect pecuniary interest in Common Stock reported in column 5 of Table I and the Stock Options (as defined below) reported in column 9 of Table II held directly by or held for the benefit of 667, a limited partnership of which the sole general partner is Baker Biotech Capital, L.P., a limited partnership of which the sole general partner is Baker Biotech Capital (GP), LLC, due to their interest in 667 and Baker Biotech Capital, L.P.'s right to receive an allocation of a portion of the profits from 667.
- F3 Pursuant to the policies of the Adviser, Julian C. Baker does not have a right to any of the Issuer's securities issued as compensation for his service on the Board and the Funds are entitled to an indirect proportionate pecuniary interest in such securities. The Funds each own an indirect proportionate pecuniary interest in the non-qualified stock options exercisable solely into Common Stock (Stock Options) and RSUs. Solely as a result of their ownership interest in (i) the general partners of the Funds and (ii) the Funds, Felix J. Baker and Julian C. Baker may be deemed to have an indirect pecuniary interest in the Stock Options, RSUs and any Common Stock acquired upon the exercise of Stock Options or vesting of RSUs (i.e. no direct pecuniary interest) issued as compensation for such Board Service.
- F4 Baker Bros. Advisors LP (the Adviser) serves as the investment adviser to the Funds. In connection with the services provided by the Adviser, the Adviser receives an asset-based management fee that does not confer any pecuniary interest in the securities held directly by the Funds or for the benefit of the Funds. The Adviser GP is the Adviser's sole general partner. Julian C. Baker and Felix J. Baker are managing members of the Adviser GP. The Adviser has complete and unlimited discretion and authority with respect to the investment and voting power of the securities held directly by the Funds or for the benefit of the Funds. The general partners of the Funds relinquished to the Adviser all discretion and authority with respect to the investment and voting power of the securities held directly by the Funds or for the benefit of the Funds.
- F5 Julian C. Baker, Felix J. Baker, the Adviser GP and the Adviser disclaim beneficial ownership of the securities held directly by or held for the benefit of the Funds except to the extent of their pecuniary interest therein, and this report shall not be deemed an admission that any of Julian C. Baker, Felix J. Baker, the Adviser GP or the Adviser is a beneficial owner of such securities for purposes of Section 16 or any other purpose.
- F6 Pursuant to the policies of the Adviser, the Adviser has voting and dispositive power over the Stock Options, RSUs and any Common Stock received as a result of the exercise of Stock Options or vesting of RSUs.
- F7 The acquisitions of the RSUs and Stock Options reported on this form represent a single grant to Julian C. Baker of 6,408 RSUs on Table I and 19,226 Stock Options on Table II. These grants, totaling 6,408 RSUs and 19,226 Stock Options for Julian C. Baker, are reported for each of the Funds as each has an indirect pecuniary interest in such securities.
| Open filing 0001193125-26-259680 Read from the filing’s XML Dispute this row |
| 2026-06-03 Filed 2026-06-05 | BAKER BROS. ADVISORS LP Director667, L.P. DirectorBaker Bros. Advisors (GP) LLC DirectorBaker Brothers Life Sciences LP DirectorBAKER FELIX DirectorBAKER JULIAN Director | A Grant, award or other acquisition pursuant to Rule 16b-3(d) Derivative security: Non- Qualified Stock Option (right to buy) — underlying Common Stock (19,226) — exercise price 19.66 | Acquired (A) | 19,226 | 0 | — | 19,226 | Indirect (I) See Footnotes | No | F10, F3, F4, F5, F6, F7, F9 - F10 19,226 Stock Options exercisable solely into Common Stock were granted under the Incentive Plan to Julian C. Baker in his capacity as a director of the Issuer. The Stock Options have a strike price of $19.66 and expire on June 3, 2036. The Stock Options vest on the earlier of June 3, 2027 or the day prior to the Issuer's Annual Meeting occurring after June 3, 2026, subject to Julian C. Baker's continuous service on the Board through such vesting date.
- F3 Pursuant to the policies of the Adviser, Julian C. Baker does not have a right to any of the Issuer's securities issued as compensation for his service on the Board and the Funds are entitled to an indirect proportionate pecuniary interest in such securities. The Funds each own an indirect proportionate pecuniary interest in the non-qualified stock options exercisable solely into Common Stock (Stock Options) and RSUs. Solely as a result of their ownership interest in (i) the general partners of the Funds and (ii) the Funds, Felix J. Baker and Julian C. Baker may be deemed to have an indirect pecuniary interest in the Stock Options, RSUs and any Common Stock acquired upon the exercise of Stock Options or vesting of RSUs (i.e. no direct pecuniary interest) issued as compensation for such Board Service.
- F4 Baker Bros. Advisors LP (the Adviser) serves as the investment adviser to the Funds. In connection with the services provided by the Adviser, the Adviser receives an asset-based management fee that does not confer any pecuniary interest in the securities held directly by the Funds or for the benefit of the Funds. The Adviser GP is the Adviser's sole general partner. Julian C. Baker and Felix J. Baker are managing members of the Adviser GP. The Adviser has complete and unlimited discretion and authority with respect to the investment and voting power of the securities held directly by the Funds or for the benefit of the Funds. The general partners of the Funds relinquished to the Adviser all discretion and authority with respect to the investment and voting power of the securities held directly by the Funds or for the benefit of the Funds.
- F5 Julian C. Baker, Felix J. Baker, the Adviser GP and the Adviser disclaim beneficial ownership of the securities held directly by or held for the benefit of the Funds except to the extent of their pecuniary interest therein, and this report shall not be deemed an admission that any of Julian C. Baker, Felix J. Baker, the Adviser GP or the Adviser is a beneficial owner of such securities for purposes of Section 16 or any other purpose.
- F6 Pursuant to the policies of the Adviser, the Adviser has voting and dispositive power over the Stock Options, RSUs and any Common Stock received as a result of the exercise of Stock Options or vesting of RSUs.
- F7 The acquisitions of the RSUs and Stock Options reported on this form represent a single grant to Julian C. Baker of 6,408 RSUs on Table I and 19,226 Stock Options on Table II. These grants, totaling 6,408 RSUs and 19,226 Stock Options for Julian C. Baker, are reported for each of the Funds as each has an indirect pecuniary interest in such securities.
- F9 After giving effect to the transactions reported herein and as a result of their ownership interest in (i) Baker Brothers Life Sciences Capital, L.P. and (ii) Life Sciences, Julian C. Baker and Felix J. Baker each may be deemed to have an indirect pecuniary interest in Common Stock reported in column 5 of Table I and the Stock Options reported in column 9 of Table II held directly by or held for the benefit of Life Sciences, a limited partnership of which the sole general partner is Baker Brothers Life Sciences Capital, L.P., a limited partnership of which the sole general partner is Baker Brothers Life Sciences Capital (GP), LLC, due to their interest in Life Sciences and Baker Brothers Life Sciences Capital, L.P.'s right to receive an allocation of a portion of the profits from Life Sciences.
| Open filing 0001193125-26-259680 Read from the filing’s XML Dispute this row |
| 2026-06-03 Filed 2026-06-05 | Cook Jennifer E. Director | A Grant, award or other acquisition pursuant to Rule 16b-3(d) Common Stock | Acquired (A) | 6,408 | 0 | — | 32,483 | Direct (D) | No | F1, F2 - F1 Each share is represented by a Restricted Stock Unit (RSU) and a contingent right to receive one share of common stock of the Issuer. 100% of the RSUs shall vest upon the earlier of (i) the one
year anniversary of the grant date or (ii) the day preceding the Issuer's next annual meeting of stockholders occurring after the grant date.
- F2 Includes 6,408 unvested RSUs.
| Open filing 0001754371-26-000002 Read from the filing’s XML Dispute this row |
| 2026-06-03 Filed 2026-06-05 | Cook Jennifer E. Director | A Grant, award or other acquisition pursuant to Rule 16b-3(d) Derivative security: Stock Option (right to buy) — underlying Common Stock (19,226) — exercise price 19.66 | Acquired (A) | 19,226 | 0 | — | 19,226 | Direct (D) | No | F3 - F3 100% of the shares subject to the option shall vest upon the earlier of (i) the one year anniversary of the grant date or (ii) the day preceding the Issuer's next annual meeting of stockholders occurring after the grant date.
| Open filing 0001754371-26-000002 Read from the filing’s XML Dispute this row |
| 2026-06-03 Filed 2026-06-05 | Van Hauwermeiren Timothy Director | A Grant, award or other acquisition pursuant to Rule 16b-3(d) Common Stock | Acquired (A) | 6,408 | 0 | — | 17,040 | Direct (D) | No | F1, F2 - F1 Each share is represented by a Restricted Stock Unit (RSU) and a contingent right to receive one share of common stock of the Issuer. 100% of the RSUs shall vest upon the earlier of (i) the one year anniversary of the grant date or (ii) the day preceding the Issuer's next annual meeting of stockholders occurring after the grant date.
- F2 Includes 17,040 unvested RSUs.
| Open filing 0001816206-26-000003 Read from the filing’s XML Dispute this row |
| 2026-06-03 Filed 2026-06-05 | Van Hauwermeiren Timothy Director | A Grant, award or other acquisition pursuant to Rule 16b-3(d) Derivative security: Stock Option (right to buy) — underlying Common Stock (19,226) — exercise price 19.66 | Acquired (A) | 19,226 | 0 | — | 19,226 | Direct (D) | No | F3 - F3 100% of the shares subject to the option shall vest upon the earlier of (i) the one year anniversary of the grant date or (ii) the day preceding the Issuer's next annual meeting of stockholders occurring after the grant date.
| Open filing 0001816206-26-000003 Read from the filing’s XML Dispute this row |
| 2026-06-03 Filed 2026-06-05 | FLATLEY JAY T Director | A Grant, award or other acquisition pursuant to Rule 16b-3(d) Common Stock | Acquired (A) | 6,408 | 0 | — | 22,628 | Direct (D) | No | F1, F2 - F1 Each share is represented by a Restricted Stock Unit (RSU) and a contingent right to receive one share of common stock of the Issuer. 100% of the RSUs shall vest upon the earlier of (i) the one year anniversary of the grant date or (ii) the day preceding the Issuer's next annual meeting of stockholders occurring after the grant date.
- F2 Includes 6,408 unvested RSUs.
| Open filing 0001189130-26-000005 Read from the filing’s XML Dispute this row |
| 2026-06-03 Filed 2026-06-05 | FLATLEY JAY T Director | A Grant, award or other acquisition pursuant to Rule 16b-3(d) Derivative security: Stock Option (right to buy) — underlying Common Stock (19,226) — exercise price 19.66 | Acquired (A) | 19,226 | 0 | — | 19,226 | Direct (D) | No | F4 - F4 100% of the shares subject to the option shall vest upon the earlier of (i) the one year anniversary of the grant date or (ii) the day preceding the Issuer's next annual meeting of stockholders occurring after the grant date.
| Open filing 0001189130-26-000005 Read from the filing’s XML Dispute this row |
| 2026-06-03 Filed 2026-06-05 | Thornberry Nancy Director | A Grant, award or other acquisition pursuant to Rule 16b-3(d) Common Stock | Acquired (A) | 6,408 | 0 | — | 31,125 | Direct (D) | No | F1, F2 - F1 Each share is represented by a Restricted Stock Unit (RSU) and a contingent right to receive one share of common stock of the Issuer. 100% of the RSUs shall vest upon the earlier of (i) the one year anniversary of the grant date or (ii) the day preceding the Issuer's next annual meeting of stockholders occurring after the grant date.
- F2 Includes 6,408 unvested RSUs.
| Open filing 0001797826-26-000002 Read from the filing’s XML Dispute this row |
| 2026-06-03 Filed 2026-06-05 | Thornberry Nancy Director | A Grant, award or other acquisition pursuant to Rule 16b-3(d) Derivative security: Stock Option (right to buy) — underlying Common Stock (19,226) — exercise price 19.66 | Acquired (A) | 19,226 | 0 | — | 19,226 | Direct (D) | No | F3 - F3 100% of the shares subject to the option shall vest upon the earlier of (i) the one year anniversary of the grant date or (ii) the day preceding the Issuer's next annual meeting of stockholders occurring after the grant date.
| Open filing 0001797826-26-000002 Read from the filing’s XML Dispute this row |
| 2026-06-03 Filed 2026-06-05 | Klein Peter S Director | A Grant, award or other acquisition pursuant to Rule 16b-3(d) Common Stock | Acquired (A) | 6,408 | 0 | — | 33,941 | Direct (D) | No | F1, F2 - F1 Each share is represented by a Restricted Stock Unit (RSU) and a contingent right to receive one share of common stock of the Issuer. 100% of the RSUs shall vest upon the earlier of (i) the one year anniversary of the grant date or (ii) the day preceding the Issuer's next annual meeting of stockholders occurring after the grant date.
- F2 Includes 6,408 unvested RSUs.
| Open filing 0001478007-26-000002 Read from the filing’s XML Dispute this row |
| 2026-06-03 Filed 2026-06-05 | Klein Peter S Director | A Grant, award or other acquisition pursuant to Rule 16b-3(d) Derivative security: Stock Option (right to buy) — underlying Common Stock (19,226) — exercise price 19.66 | Acquired (A) | 19,226 | 0 | — | 19,226 | Direct (D) | No | F3 - F3 100% of the shares subject to the option shall vest upon the earlier of (i) the one year anniversary of the grant date or (ii) the day preceding the Issuer's next annual meeting of stockholders occurring after the grant date.
| Open filing 0001478007-26-000002 Read from the filing’s XML Dispute this row |
| 2026-01-06 Filed 2026-01-08 | Schuth Alexander O. Officer: COFO and Secretary | S Open market or private sale of non-derivative or derivative security Common Stock | Disposed (D) | 17,218 | 16.50 | 284,097 Derived: shares × price per share. Exact value 284097.00. | 282,828 | Direct (D) | No | F1, F2 - F1 Shares sold to satisfy the tax obligations by the Reporting Person in connection with the settlement of previously vested RSUs.
- F2 Includes 141,100 Unvested RSUs.
| Open filing 0001724311-26-000005 Read from the filing’s XML Dispute this row |
| 2026-01-06 Filed 2026-01-08 | Watts Ryan J. Director · Officer: President and CEO | S Open market or private sale of non-derivative or derivative security Common Stock | Disposed (D) | 35,198 | 16.50 | 580,767 Derived: shares × price per share. Exact value 580767.00. | 296,833 | Direct (D) | No | F1, F2 - F1 Shares sold to satisfy the tax obligations by the Reporting Person in connection with the settlement of previously vested RSUs.
- F2 Includes 184,915 Unvested RSUs.
| Open filing 0001724310-26-000004 Read from the filing’s XML Dispute this row |
| 2026-01-03 Filed 2026-01-05 | Watts Ryan J. Director · Officer: President and CEO | A Grant, award or other acquisition pursuant to Rule 16b-3(d) Common Stock | Acquired (A) | 78,960 | 0 | — | 332,031 | Direct (D) | No | F1, F2 - F1 Each share is represented by a Restricted Stock Unit (RSU) and a contingent right to receive one share of common stock of the Issuer. 25% of the RSUs shall vest on January 3, 2027 (the Vesting
Commencement Date) and an additional 25% of the RSUs shall vest on each annual anniversary of the Vesting Commencement Date thereafter, subject to the Reporting Person remaining a service
provider of the Issuer through each such date.
- F2 Includes 184,915 Unvested RSUs.
| Open filing 0001724310-26-000001 Read from the filing’s XML Dispute this row |
| 2026-01-03 Filed 2026-01-05 | Watts Ryan J. Director · Officer: President and CEO | A Grant, award or other acquisition pursuant to Rule 16b-3(d) Derivative security: Stock Option (right to buy) — underlying Common Stock (236,880) — exercise price 16.27 | Acquired (A) | 236,880 | 0 | — | 236,880 | Direct (D) | No | F4 - F4 25% of the shares subject to the option shall vest on January 3, 2027, and 1/48 of the shares subject to the option shall vest each month thereafter, subject to the Reporting Person remaining a service provider of the Issuer through each such date
| Open filing 0001724310-26-000001 Read from the filing’s XML Dispute this row |
| 2026-01-03 Filed 2026-01-05 | Schuth Alexander O. Officer: COFO and Secretary | A Grant, award or other acquisition pursuant to Rule 16b-3(d) Common Stock | Acquired (A) | 57,700 | 0 | — | 300,046 | Direct (D) | No | F1, F2 - F1 Each share is represented by a Restricted Stock Unit (RSU) and a contingent right to receive one share of common stock of the Issuer. 25% of the RSUs shall vest on January 3, 2027 (the Vesting
Commencement Date) and an additional 25% of the RSUs shall vest on each annual anniversary of the Vesting Commencement Date thereafter, subject to the Reporting Person remaining a service
provider of the Issuer through each such date.
- F2 Includes 141,100 Unvested RSUs.
| Open filing 0001724311-26-000001 Read from the filing’s XML Dispute this row |
| 2026-01-03 Filed 2026-01-05 | Schuth Alexander O. Officer: COFO and Secretary | A Grant, award or other acquisition pursuant to Rule 16b-3(d) Derivative security: Stock Option (right to buy) — underlying Common Stock (173,100) — exercise price 16.27 | Acquired (A) | 173,100 | 0 | — | 173,100 | Direct (D) | No | F4 - F4 25% of the shares subject to the option shall vest on January 3, 2027, and 1/48 of the shares subject to the option shall vest each month thereafter, subject to the Reporting Person remaining a service provider of the Issuer through each such date.
| Open filing 0001724311-26-000001 Read from the filing’s XML Dispute this row |
| 2025-12-11 Filed 2025-12-15 | BAKER BROS. ADVISORS LP Director667, L.P. DirectorBaker Bros. Advisors (GP) LLC DirectorBaker Brothers Life Sciences LP DirectorBAKER FELIX DirectorBAKER JULIAN Director | P Open market or private purchase of non-derivative or derivative security Derivative security: $0.01 Prefunded Warrants — underlying Common Stock (190,523) — exercise price 0.01 | Acquired (A) | 190,523 | 17.49 | 3,332,247.27 Derived: shares × price per share. Exact value 3332247.27. | 2,335,469 | Indirect (I) See Footnotes | No | F1, F2, F3, F4, F5 - F1 667, L.P. (667) and Baker Brothers Life Sciences, L.P. (Life Sciences and together with 667, the Funds) purchased, respectively, 190,523 and 2,095,191 warrants to purchase common stock (Common Stock) of Denali Therapeutics Inc. (the Issuer) at an exercise price of $0.01 per share with no expiration date ($0.01 Prefunded Warrants) for $17.49 per share in a public offering that closed on December 11, 2025.
- F2 The $0.01 Prefunded Warrants are exercisable at any time, at the holder's election, on a 1-for-1 basis into Common Stock to the extent that immediately prior to or after giving effect to such exercise the holders thereof, together with their affiliates and any members of a Section 13(d) group with such holders, would beneficially own, for purposes of Rule 13d-3 under the Securities Act of 1934, as amended, no more thn 4.99% of the outstanding shares of Common Stock (the Maximum Percentage). By written notice to the Issuer, the Funds may increase or decrease the Maximum Percentage applicable to that fund to any other percentage not in excess of 19.99%; provided that any such increase will not be effective until the 61st day after such notice is delivered to the Issuer.
- F3 After giving effect to the transactions reported herein and as a result of their ownership interest in (i) Baker Biotech Capital, L.P. and (ii) 667, Julian C. Baker and Felix J. Baker each may be deemed to have an indirect pecuniary interest in the securities reported in column 9 of Table II held directly by 667, a limited partnership of which the sole general partner is Baker Biotech Capital, L.P., a limited partnership of which the sole general partner is Baker Biotech Capital (GP), LLC, due to their interest in 667 and Baker Biotech Capital, L.P.'s right to receive an allocation of a portion of the profits from 667.
- F4 Baker Bros. Advisors LP (the Adviser) serves as the investment adviser to the Funds. In connection with the services provided by the Adviser, the Adviser receives an asset-based management fee that does not confer any pecuniary interest in the securities held directly by the Funds. The Adviser GP is the Adviser's sole general partner. Julian C. Baker and Felix J. Baker are managing members of the Adviser GP. The Adviser has complete and unlimited discretion and authority with respect to the investment and voting power of the securities held directly by the Funds. The general partners of the Funds relinquished to the Adviser all discretion and authority with respect to the investment and voting power of the securities held directly by the Funds.
- F5 Julian C. Baker, Felix J. Baker, the Adviser GP and the Adviser disclaim beneficial ownership of the securities held directly by the Funds except to the extent of their pecuniary interest therein, and this report shall not be deemed an admission that any of Julian C. Baker, Felix J. Baker, the Adviser GP or the Adviser is a beneficial owner of such securities for purposes of Section 16 or any other purpose.
| Open filing 0001193125-25-319291 Read from the filing’s XML Dispute this row |
| 2025-12-11 Filed 2025-12-15 | BAKER BROS. ADVISORS LP Director667, L.P. DirectorBaker Bros. Advisors (GP) LLC DirectorBaker Brothers Life Sciences LP DirectorBAKER FELIX DirectorBAKER JULIAN Director | P Open market or private purchase of non-derivative or derivative security Derivative security: $0.01 Prefunded Warrants — underlying Common Stock (2,095,191) — exercise price 0.01 | Acquired (A) | 2,095,191 | 17.49 | 36,644,890.59 Derived: shares × price per share. Exact value 36644890.59. | 25,996,310 | Indirect (I) See Footnotes | No | F1, F2, F4, F5, F6 - F1 667, L.P. (667) and Baker Brothers Life Sciences, L.P. (Life Sciences and together with 667, the Funds) purchased, respectively, 190,523 and 2,095,191 warrants to purchase common stock (Common Stock) of Denali Therapeutics Inc. (the Issuer) at an exercise price of $0.01 per share with no expiration date ($0.01 Prefunded Warrants) for $17.49 per share in a public offering that closed on December 11, 2025.
- F2 The $0.01 Prefunded Warrants are exercisable at any time, at the holder's election, on a 1-for-1 basis into Common Stock to the extent that immediately prior to or after giving effect to such exercise the holders thereof, together with their affiliates and any members of a Section 13(d) group with such holders, would beneficially own, for purposes of Rule 13d-3 under the Securities Act of 1934, as amended, no more thn 4.99% of the outstanding shares of Common Stock (the Maximum Percentage). By written notice to the Issuer, the Funds may increase or decrease the Maximum Percentage applicable to that fund to any other percentage not in excess of 19.99%; provided that any such increase will not be effective until the 61st day after such notice is delivered to the Issuer.
- F4 Baker Bros. Advisors LP (the Adviser) serves as the investment adviser to the Funds. In connection with the services provided by the Adviser, the Adviser receives an asset-based management fee that does not confer any pecuniary interest in the securities held directly by the Funds. The Adviser GP is the Adviser's sole general partner. Julian C. Baker and Felix J. Baker are managing members of the Adviser GP. The Adviser has complete and unlimited discretion and authority with respect to the investment and voting power of the securities held directly by the Funds. The general partners of the Funds relinquished to the Adviser all discretion and authority with respect to the investment and voting power of the securities held directly by the Funds.
- F5 Julian C. Baker, Felix J. Baker, the Adviser GP and the Adviser disclaim beneficial ownership of the securities held directly by the Funds except to the extent of their pecuniary interest therein, and this report shall not be deemed an admission that any of Julian C. Baker, Felix J. Baker, the Adviser GP or the Adviser is a beneficial owner of such securities for purposes of Section 16 or any other purpose.
- F6 After giving effect to the transactions reported herein and as a result of their ownership interest in (i) Baker Brothers Life Sciences Capital, L.P. and (ii) Life Sciences, Julian C. Baker and Felix J. Baker each may be deemed to have an indirect pecuniary interest in the securities reported in column 9 of Table II held directly by Life Sciences, a limited partnership of which the sole general partner is Baker Brothers Life Sciences Capital, L.P., a limited partnership of which the sole general partner is Baker Brothers Life Sciences Capital (GP), LLC, due to their interest in Life Sciences and Baker Brothers Life Sciences Capital, L.P.'s right to receive an allocation of a portion of the profits from Life Sciences.
| Open filing 0001193125-25-319291 Read from the filing’s XML Dispute this row |